CN104258085A - Preparation method of Tibetan drug for treating influenza - Google Patents

Preparation method of Tibetan drug for treating influenza Download PDF

Info

Publication number
CN104258085A
CN104258085A CN201410564895.1A CN201410564895A CN104258085A CN 104258085 A CN104258085 A CN 104258085A CN 201410564895 A CN201410564895 A CN 201410564895A CN 104258085 A CN104258085 A CN 104258085A
Authority
CN
China
Prior art keywords
radix
preparation
*** medicine
group
active component
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201410564895.1A
Other languages
Chinese (zh)
Inventor
不公告发明人
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Qinghai Tongtianhe Tibetan Medicine Pharmacy Co Ltd
Original Assignee
Qinghai Tongtianhe Tibetan Medicine Pharmacy Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Qinghai Tongtianhe Tibetan Medicine Pharmacy Co Ltd filed Critical Qinghai Tongtianhe Tibetan Medicine Pharmacy Co Ltd
Priority to CN201410564895.1A priority Critical patent/CN104258085A/en
Publication of CN104258085A publication Critical patent/CN104258085A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
    • A61K36/714—Aconitum (monkshood)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/09—Lichens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/34—Campanulaceae (Bellflower family)
    • A61K36/344—Codonopsis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/51—Gentianaceae (Gentian family)
    • A61K36/515—Gentiana
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/898—Orchidaceae (Orchid family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/10—Preparation or pretreatment of starting material
    • A61K2236/15—Preparation or pretreatment of starting material involving mechanical treatment, e.g. chopping up, cutting or grinding
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/55—Liquid-liquid separation; Phase separation

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention discloses a preparation method of a Tibetan drug for treating influenza. The preparation method comprises the following steps: preparing an active ingredient from aconitum pendulum seedlings, poliothamnus diels, thallus theloschestei flavicani, phlomis younghusbandii, codonopsis convolvulacea, edelweiss, rhizoma bletillae, saxifraga pasumensis and radix gentianae according to a certain weight ratio by a mixed grinding method, a water extraction and alcohol sedimentation method or an alcohol extraction and water sedimentation method. The Tibetan drug can be prepared into any one common dosage form for oral administration, has the effects of clearing heat, eliminating inflammation and removing toxic materials, and is used for treating the influenza, rhinorrhea, headache and cough, pain in whole body, inflammation, fever and the like.

Description

A kind of preparation method for the treatment of influenza Tibetan medicine
Technical field
The present invention relates to a kind of preparation method for the treatment of influenza Tibetan medicine, belong to Tibetan medicine field.
Background technology
Influenza is the Acute respiratory infectious disease that influenza virus causes, and is mankind's public health problems, is also the important infectious disease causing human death.Belong to common clinical, frequently-occurring disease, all have generation throughout the year.This disease is strong with infectiousness, propagate rapidly for characteristics of incidence, Pneumology Department old man, to have a delicate constitution and therefore sub-health population often goes to a doctor.
According to statistics, the every annual morbidity of influenza reaches 10 ~ 30%.The annual influenza pandemic in the whole world can cause the serious flu cases of 300 ~ 5,000,000, annual death toll nearly 25 ten thousand to 50 ten thousand.Significant impact is brought to the public health in the whole world, all many-sides of economic dispatch.And China is the district occurred frequently of influenza.Due to severe symptoms, onset is anxious, and infectiousness is strong, and sickness rate is high, is subject to people's extensive concern.
For the treatment that viral upper respiratory infects, western medical treatment principle to bring down a fever, antiinflammatory and symptomatic treatment.Chinese medicine thinks that influenza belongs to " exterior syndrome " and " outer pathogenies ", and the cause of disease is that warm poison is evil, and its pathogenesis is that outer temperature-sensing thermal poison evil invasion and attack lung is defended, and the gas defending sun freely in outward, can not cause lung and defend closing, thus see fever with aversion to cold, card that the lung such as watery nasal discharge, pharyngalgia cough of having a stuffy nose is defended.Method for the treatment of with clear, separate, declare, fall apart for main method.In Tibetanmedicine, the scope that influenza belongs to " pestilence ", generally believes it is the gas of impression filth, infectious disease that air etc. that the pathogenic QI in the body of patient's exhalation and body odor, flue dust, the gas of scrofula, poison and epidemic-stricken area blow causes.
Although the medicine of the popular sexuality of current treatment is a lot, curative effect still can not be satisfactory.Therefore, people better treat grippal Tibetan medicinal preparation to curative effect and still there is tight demand.
Up to now, any report about Tibetan medicinal composition of the present invention and preparation method thereof is not also found.The present inventor through repeatedly studying, and by the checking repeatedly of animal and clinical trial, grippal Tibetan medicine oral drugs for the treatment of that finally have found better curative effect and preparation method thereof, thus complete the present invention.
Summary of the invention
The object of the invention is just to provide a kind of preparation method of more effectively treating influenza Tibetan medicine.
Tibetan medicine of the present invention is made up of active component or is made up of active component and pharmaceutically acceptable adjuvant, and wherein said active component is made up of following bulk drugs: Radix aconiti szechenyiani seedling, Radix Asteris poliothamni, wall tapestry, Radix phlomidis younghusbandii, Radix Codonopsis Convolvulaceae, Leontopodium leontopodioides (Willd.) Beauv., Pseudobulbus Bletillae (Rhizoma Bletillae), pectinate rockfoil, assorted flower Radix Gentianae.
It has selected Radix aconiti szechenyiani seedling, Radix Asteris poliothamni, wall tapestry, Radix phlomidis younghusbandii, Radix Codonopsis Convolvulaceae, Leontopodium leontopodioides (Willd.) Beauv., Pseudobulbus Bletillae (Rhizoma Bletillae), pectinate rockfoil, mixes and spend Radix Gentianae to carry out combining as crude drug, and wherein (1) Radix aconiti szechenyiani seedling is the dry seedling of cohosh Aconitum flavum Hand-Mazz Aconitum flavum Hand.Mazz. and Radix aconiti szechenyiani A.pendulumBusch..There is heat clearing away, effect of pain relieving.For influenza, pestilence, pyretic toxicity, skin ulcer furuncle.(2) Radix Asteris poliothamni is the dried floral of feverfew Radix Asteris poliothamni Aster poliothamnus Didls.There is effect of heat-clearing and toxic substances removing.For pestilence epidemic disease, Baconic is sick, arteries and veins heat.(3) wall tapestry is the dry thallus of lichens Teloshistaceae plant wall tapestry Theloschestes flavicans (Sw.) Norm.There is heat extraction, effect of removing toxic substances.For lung-heat, liver-heat, arteries and veins heat, scorchingly hot.(4) Radix phlomidis younghusbandii is the dried root of labiate Radix phlomidis younghusbandii Phlomis younghusbandii Mukerjee.There is cold expelling wet one's whistle, effect of holder skin ulcer granulation promoting.For Baconic's sympotoms caused by cold factors, throat epidemic disease, pneumonopathy, cold cough, bronchitis, skin ulcer of a specified duration does not heal.(5) Radix Codonopsis Convolvulaceae descends tuber dryly for Campanulaceae Radix Codonopsis Convolvulaceae Codonopsis convolvulacea kurz.There is effect of invigorating QI and blood, spleen invigorating, replenishing body fluid and clearing away heat pathogen.For flu, cough, tonsillitis, chest pain, inappetence, malnutrition.(6) Leontopodium leontopodioides (Willd.) Beauv. is the aerial parts of feverfew Leontopodium leontopodioides (Willd.) Beauv. Leontopodium leontopodioides (Willd.) Beauv..There is heat-clearing and toxic substances removing, effect of hemostasis.For influenza, pestilence, lymphadenitis, mineral drug is poisoning, the hemorrhage disease that Dengs.(7) Pseudobulbus Bletillae (Rhizoma Bletillae) is the dry tuber of orchid Pseudobulbus Bletillae (Rhizoma Bletillae) Bletilla striata (Thunb.) Reichb.f..There is eliminating inflammation and expelling toxin, effect of appetizing.For parasitosis, epidemic disease is caught a cold, calentura, dyspepsia, gallbladder disease, and red bar is sick.(8) pectinate rockfoil is the dry herb of saxifragaceae plant Herba Saxifragae umbellalatae Saxifraga umbellulata Hook.f.et, Thoms.var.pectinata (Marq et Airy-Shaw) J.T.Pan.There is the heat of liver heat removing gallbladder, effect of evacuation of pus sore.For liver-heat, gallbladder heat, epidemic disease cat fever and skin ulcer heat etc.(9) assorted flower Radix Gentianae is the root and rhizome of gentianaceae plant Gentiana veitchiorum Gentiana veitchiorum Hemsl. and cloud and mist Radix Gentianae Gentiana nubigena Edgew..There is clearing away damp-heat, eliminating pathogen in the liver gallbladder excess-fire, antitussive, sharp larynx, effect of stomach invigorating.For cat fever, conjunctival congestion pharyngalgia, cough due to lung-heat, gastric heat, brain acute diseases such as cholera and sunstroke, urethral fever, pudendal pruritus and vulval eczema, variola.These crude drug are combinationally used and makes each crude drug effect produce synergism, thus effectively can treat influenza.
The consumption of Tibetan medicine active component of the present invention is also through inventor and gropes in a large number to sum up and draw, each crude drug consumption for all to have good therapeutic effect within the scope of following concrete weight proportion:
Radix aconiti szechenyiani seedling 2.5 ~ 7.5g, Radix Asteris poliothamni 30 ~ 90g, wall tapestry 20 ~ 60g, Radix phlomidis younghusbandii 25 ~ 75g, Radix Codonopsis Convolvulaceae 25 ~ 75g, Leontopodium leontopodioides (Willd.) Beauv. 20 ~ 60g, Pseudobulbus Bletillae (Rhizoma Bletillae) 15 ~ 45g, pectinate rockfoil 15 ~ 45g, assorted flower Radix Gentianae 15 ~ 45g.
Be preferably: Radix aconiti szechenyiani seedling 4 ~ 6g, Radix Asteris poliothamni 48 ~ 72g, wall tapestry 32 ~ 48g, Radix phlomidis younghusbandii 40 ~ 60g, Radix Codonopsis Convolvulaceae 40 ~ 60g, Leontopodium leontopodioides (Willd.) Beauv. 32 ~ 48g, Pseudobulbus Bletillae (Rhizoma Bletillae) 24 ~ 36g, pectinate rockfoil 24 ~ 36g, assorted flower Radix Gentianae 24 ~ 36g.
More preferably: Radix aconiti szechenyiani seedling 5g, Radix Asteris poliothamni 60g, wall tapestry 40g, Radix phlomidis younghusbandii 50g, Radix Codonopsis Convolvulaceae 50g, Leontopodium leontopodioides (Willd.) Beauv. 40g, Pseudobulbus Bletillae (Rhizoma Bletillae) 30g, pectinate rockfoil 30g, assorted flower Radix Gentianae 30g.
The preparation of Tibetan medicine active component of the present invention can be pulverized by the crude drug convection drying of above-mentioned consumption to make; Also the crude drug of above-mentioned consumption can be adopted the conventional method of Chinese medicine preparation such as decoction and alcohol sedimentation technique or ethanol extract from water precipitation (see " pharmaceutics of Chinese drugs " 73-74 page of Cao Chunlin chief editor, Science and Technology of Shanghai publishing house publishes in November, 1986) to obtain.
The active component of Tibetan medicine of the present invention can add various customary adjuvant required when preparing different dosage form, as disintegrating agent, lubricant, binding agent etc. with the method for Chinese medicinal of routine (see Cao Chunlin chief editor " pharmaceutics of Chinese drugs ", Science and Technology of Shanghai publishing house in November, 1986 publishes) be prepared into any one and commonly use peroral dosage form, as powder, pill, capsule, granule, tablet etc.
Tibetan medicine of the present invention has heat clearing away, antiinflammatory, effect of removing toxic substances.For influenza, flow clear nasal mucus, headache cough, malasia, inflammation fever etc.
The usage and dosage of Tibetan medicine of the present invention is: oral; A 1 ~ 1.5g, 1 ~ 3 time on the one.
[detailed description of the invention]
Carry out the preparation method setting forth Tibetan medicine of the present invention further by the following examples.
The preparation of [embodiment 1] Tibetan medicine powder of the present invention:
Take Radix aconiti szechenyiani seedling 5g, Radix Asteris poliothamni 60g, wall tapestry 40g, Radix phlomidis younghusbandii 50g, Radix Codonopsis Convolvulaceae 50g, Leontopodium leontopodioides (Willd.) Beauv. 40g, Pseudobulbus Bletillae (Rhizoma Bletillae) 30g, pectinate rockfoil 30g, assorted flower Radix Gentianae 30g, be jointly ground into fine powder after mixing, mixing, subpackage, obtains powder.
The preparation of [embodiment 2] Tibetan medicine pill of the present invention:
Take Radix aconiti szechenyiani seedling 2.5g, Radix Asteris poliothamni 30g, wall tapestry 20g, Radix phlomidis younghusbandii 25g, Radix Codonopsis Convolvulaceae 25g, Leontopodium leontopodioides (Willd.) Beauv. 20g, Pseudobulbus Bletillae (Rhizoma Bletillae) 15g, pectinate rockfoil 15g, assorted flower Radix Gentianae 15g; jointly fine powder is ground into after mixing; mixing; with water pill; dry below 60 DEG C; polishing, packaging, obtains pill.
The preparation of [embodiment 3] Tibetan medicine granule of the present invention:
Take Radix aconiti szechenyiani seedling 7.5g, Radix Asteris poliothamni 90g, wall tapestry 60g, Radix phlomidis younghusbandii 75g, Radix Codonopsis Convolvulaceae 75g, Leontopodium leontopodioides (Willd.) Beauv. 60g, Pseudobulbus Bletillae (Rhizoma Bletillae) 45g, pectinate rockfoil 45g, assorted flower Radix Gentianae 45g; jointly fine powder is ground into after mixing; mixing; add adjuvant and make granule; dry below 60 DEG C; granulate, subpackage, obtains granule.
The preparation of [embodiment 4] Tibetan medicine capsule of the present invention:
Take Radix aconiti szechenyiani seedling 4g, Radix Asteris poliothamni 48g, wall tapestry 32g, Radix phlomidis younghusbandii 40g, Radix Codonopsis Convolvulaceae 40g, Leontopodium leontopodioides (Willd.) Beauv. 32g, Pseudobulbus Bletillae (Rhizoma Bletillae) 24g, pectinate rockfoil 24g, assorted flower Radix Gentianae 24g; jointly fine powder is ground into after mixing; mixing, loads gelatine capsule, obtains capsule.
The preparation of [embodiment 5] Tibetan medicine tablet of the present invention:
Take Radix aconiti szechenyiani seedling 6g, Radix Asteris poliothamni 72g, wall tapestry 48g, Radix phlomidis younghusbandii 60g, Radix Codonopsis Convolvulaceae 60g, Leontopodium leontopodioides (Willd.) Beauv. 48g, Pseudobulbus Bletillae (Rhizoma Bletillae) 36g, pectinate rockfoil 36g, assorted flower Radix Gentianae 36g; jointly fine powder is ground into after mixing; mixing; add adjuvant and make granule; dry below 60 DEG C; granulate, tabletting, obtains tablet.
Set forth the beneficial effect of Tibetan medicine of the present invention further below by way of test example, these test examples include pharmacodynamics test and the clinical observation on the therapeutic effect test of Tibetan medicine embodiment 1 powder of the present invention.
[test example 1] Tibetan medicine embodiment 1 of the present invention powder is to the pharmacodynamics test of antipyretic, analgesia, antiinflammatory, cough-relieving, phlegm-dispelling functions:
Test material: anthology invention Tibetan medicine embodiment 1 powder is trial drug; SUNJU GANMAO PIAN is produced by Chinese medicine refinery of Beijing Tongrentang, lot number 20100809; Dry yeast is produced by Hubei Angel Yeast Co., Ltd, lot number 20100804; Glacial acetic acid is produced by Shanghai reagent four factory, lot number 20100403; NIH mice, Wistar rat, provide by Lanzhou Experimental Animal Center.
Experimental technique and result: 1, rat temperature elevation model, animal grouping and medication: get the normal rat 50 in body weight (190 ± 20g), body temperature (36.6 ~ 38.3 DEG C) scope, in the subnormal body temperature of administration before measurement 2, and get its average and be worth as before medicine.After through rat back subcutaneous injection 20% sterilised yeast suspension 10ml/Kg body weight, the rat of more than 0.8 DEG C of being risen by body temperature after 4h is divided into 5 groups at random, be respectively model group, positive controls (SUNJU GANMAO PIAN 3.6g/Kg) and Tibetan medicine embodiment 1 powder (1.5g/kg of the present invention, 3g/kg, 6g/kg) basic, normal, high dosage group, gastric infusion 20ml/Kg, model group is to equivalent distilled water.Measure 1 body temperature every 1h after administration, survey 4 times altogether, the results are shown in Table 1.
Table 1 Tibetan medicine embodiment 1 of the present invention powder is to the refrigeration function (x ± s, n=10) of heating rat
Body temperature (DEG C) after body temperature administration after group normal body temperature pyrogenicity
（℃） （℃） 1h 2h 3h 4h
Model control group 37.58 ± 0.43 39.17 ± 0.77 39.30 ± 0.62 39.20 ± 0.43 38.91 ± 0.62 38.63 ± 0.57
Positive controls 37.55 ± 0.41 39.18 ± 0.79 38.67 ± 0.56 *38.70 ± 0.55 *38.74 ± 0.54 38.62 ± 0.56
Low dose group 37.39 ± 0.56 39.00 ± 0.74 39.00 ± 0.78 38.74 ± 0.75 38.64 ± 0.64 38.40 ± 0.66
Middle dosage group 37.52 ± 0.45 39.18 ± 0.69 38.68 ± 0.54 38.66 ± 0.58 38.56 ± 0.45 38.52 ± 0.56
High dose group 37.53 ± 0.44 39.14 ± 0.63 38.69 ± 0.57 *38.64 ± 0.58 *38.55 ± 0.52 38.53 ± 0.51
Illustrate: compare with model control group: *p<0.05.
From table 1, rat temperature caused by dry yeast can be made after high doses applied group to raise and obviously reduce, low dose group then acts on not obvious.
2, pain model in mice, animal grouping and medication: get mice 50, be divided into 5 groups at random, if model group, positive controls (SUNJU GANMAO PIAN 3.6g/Kg) and Tibetan medicine embodiment 1 powder (1.5g/kg of the present invention, 3g/kg, 6g/kg) low, in, high dose group, gastric infusion, 20ml/Kg, every day is administered once, continuous 2d, model group is to normal saline, after last administration, 30min each Mus lumbar injection 0.6% glacial acetic acid 0.1ml/10g causes pain model in mice, observe writhing number of times in incubation period and 30min that the reaction of each group of mouse writhing occurs, the results are shown in Table 2.
Table 2 Tibetan medicine embodiment 1 of the present invention powder is on the impact (x ± s, n=10) of glacial acetic acid induced pain mice
Group Animals number dosage (g/kg) incubation period (min) writhing number of times (secondary/30min)
Model control group 10 3.57 ± 2.26 41.58 ± 21.16
Positive controls 10 3.6 4.48 ± 3.22 27.73 ± 8.54
Low dose group 10 1.5 3.23 ± 1.13 22.58 ± 6.58 *
Middle dosage group 10 3 9.69 ± 8.22 *11.43 ± 9.38 *
High dose group 10 6 13.41 ± 4.34 * *9.83 ± 6.39 * *
Illustrate: compare with model control group: *p<0.05; *p<0.01; * *p<0.OOl.
As seen from Table 2: in Tibetan medicine embodiment 1 powder of the present invention, dosage group obviously can extend the incubation period of glacial acetic acid induced pain mouse writhing reaction, more than low dose group all can reduce the number of times of writhing in 30min, compare with model control group, there is significant difference (P<0.05, P<0.01); And this effect of high dose group significantly (P<0.001).
3, mice auricle swelling model, animal grouping and medication: get mice 50, be divided into model group, positive controls (SUNJU GANMAO PIAN 3.6g/Kg) and Tibetan medicine embodiment 1 powder (1.5g/kg of the present invention at random, 3g/kg, 6g/kg) basic, normal, high dosage group, gastric infusion, 40ml/Kg, every day is administered once, continuous 3d, and model group is to equivalent distilled water, after last medicine 1h 30 μ l dimethylbenzene are applied to mouse right ear exterior feature before and after two sides cause inflammation, and with left auricle in contrast.Cause scorching rear 30min by sacrifice, cut ears, lay the auricle of left and right ear same area with 0.9cm standard hole device.Analytical balance is weighed, and the difference of left and right auricle weight is swelling, the results are shown in Table 3.
Table 3 Tibetan medicine embodiment 1 of the present invention powder xylol causes the impact (x ± s, n=10) of mice auricle swelling
Group Animals number dosage (g/kg) ears weight difference (mg) p
Model control group 10 26.59 ± 4.38
Positive controls 10 3.6 19.51 ± 54.25 <0.01
Low dose group 10 1.5 22.62 ± 6.36 >0.05
Middle dosage group 10 3 20.87 ± 4.14 >0.05
High dose group 10 6 17.49 ± 3.31 <0.05
As seen from Table 3: Tibetan medicine embodiment 1 powder high dose group of the present invention can make mice auricle swelling obviously alleviate, show that Tibetan medicine embodiment 1 powder of the present invention has obvious antiinflammatory action.
4, antitussive mouse model, animal grouping and medication: get mice 50, be divided into model group, positive controls (SUNJU GANMAO PIAN 3.6g/Kg) and Tibetan medicine embodiment 1 powder (1.5g/kg, 3g/kg of the present invention at random, 6g/kg) basic, normal, high dosage group, gastric infusion, 40ml/Kg, every day is administered once, continuous 3d, model group is to equivalent distilled water, and 1h after last medicine, gets mice 1 for each group, be placed in a glass bell jar, cover infantile tic has a filter paper (2 × 2cm 2), by 0.5ml ammonia (25% ~ 28%NH 4oH) drip on filter paper and stimulate mice.Take out mice after 1min, observe and record cough number of times in mouse cough incubation period and 2min, the results are shown in 4.
Table 4 Tibetan medicine embodiment 1 of the present invention powder is on the impact (x ± s, n=10) of mouse cough number of times and cough latent period
Group Animals number dosage (g/kg) is coughed number of times (secondary/2min) cough latent period (min) P
Model control group 10 14.83 ± 7.49 0.57 ± 0.27
Positive controls 10 3.6 8.91 ± 4.37 0.95 ± 0.28 <0.05
Low dose group 10 1.5 15.28 ± 6.43 0.57 ± 0.29 >0.05
Middle dosage group 10 3 10.61 ± 5.13 0.74 ± 0.22 >0.05
High dose group 10 6 7.89 ± 4.35 0.98 ± 0.23 <0.05
As seen from Table 4: Tibetan medicine embodiment 1 powder high dose group of the present invention obviously can extend mouse cough incubation period and reduce the cough number of times (P<0.05) of mice, but low dose group effect is not obvious.
5, eliminate the phlegm mouse model, animal grouping and medication: get mice 50, be divided into model group, positive controls (SUNJU GANMAO PIAN 3.6g/Kg) and Tibetan medicine embodiment 1 powder (1.5g/kg, 3g/kg of the present invention at random, 6g/kg) basic, normal, high dosage group, gastric infusion, 40ml/Kg, every day is administered once, continuous 3d, model group to equivalent distilled water, 1h after last medicine, every Mus is through the phenol red normal saline 50ml/Kg of lumbar injection 0.25%, after 30min, cervical dislocation is put to death, and uses 5%NaHCO 3lavation mice trachea-bronchial epithelial cell 3 times, each 0.5ml, collects irrigating solution 1.5ml altogether, centrifugal.Get supernatant spectrophotometer in 520nm wavelength place colorimetric, survey phenol red output (OD value), the results are shown in 5.
Table 5 Tibetan medicine of the present invention embodiment 1 powder is on the impact (x ± s, n=10) of the phenol red secretory volume of mice
Group Animals number dosage (g/kg) phenol red amount (OD value) P
Model control group 10 0.173 ± 0.027
Positive controls 10 3.6 0.251 ± 0.012 <0.05
Low dose group 10 1.5 0.185 ± 0.032 >0.05
Middle dosage group 10 3 0.226 ± 0.031 >0.05
High dose group 10 6 0.261 ± 0.049 <0.05
As seen from Table 5: the phenol red secretory volume of Tibetan medicine embodiment 1 powder high dose group of the present invention comparatively model control group obviously increases (P<0.05), show that Tibetan medicine embodiment 1 powder of the present invention can increase the secretory function of trachea-bronchial epithelial cell mucosa, sputum viscosity is declined, be easy to expectoration, thus play eliminate the phlegm, antiasthmatic effect.
[test example 2] Tibetan medicine embodiment 1 powder treatment of the present invention influenza clinical observation on the therapeutic effect:
Physical data: in 120 routine patients with influenzas, all meet the diagnostic criteria of influenza, wherein man 53 example, female 67 example; Age at 18 ~ 60 years old, average 33 ± 9.6; The course of disease 2 ~ 48h, average 22.8h; Body temperature 37.9 DEG C ~ 39.8 DEG C, average 38.4 DEG C.According to medical order, patient is divided into two groups at random, treatment group and each 60 examples of matched group.Two groups are compared in sex, age, the course of disease, body temperature etc., and no significant difference (P ﹥ 0.05), has comparability.
Diagnostic criteria: with reference to the diagnostic criteria in " influenza clinical diagnosis and the treatment guidelines " and " new Chinese medicine clinical treatment guideline " of respirology branch of Chinese Medical Association formulation in 2005.Detailed rules and regulations are as follows, primary symptom: 1. generate heat (T>37 DEG C); 2. tired, breast gastral cavity painful abdominal mass is vexed, poor appetite, and xerostomia is not for drink, and loose stool, feels sick, vomiting; 3. soft and rapid pulse, tongue fur HUANGBAI(sic) and greasy or yellow greasy.Secondary disease: pharyngalgia, cough, watery nasal discharge, nasal obstruction, pharyngeal congestion, dizzy headache, oliguria with reddish urine.
Inclusive criteria: 1. meet above diagnostic criteria; 2. the range of age, between 18 ~ 60 years old; 3. the course of disease is within 48 h.
Exclusion standard: 1. routine blood test, total white blood cells >10 × 109/L and (or) neutrophilic granulocyte percentage ratio >70%; 2. without heating person; 3. the damp and hot class patient of epidemic febrile disease is not belonged to; 4. occur together bronchitis and (or) pneumonia; 5. gestation or women breast-feeding their children; 6. the serious primary disease of other system is associated with.
Therapeutic Method: treatment group: adopt Tibetan medicine embodiment 1 powder of the present invention, 1.5g/ time, 1 day 3 times, oral.Course for the treatment of of taking medicine is 3 days.Matched group: take Lingyangganmao Capsules, 0.6g/ time, 1 day 3 times, oral.Course for the treatment of of taking medicine is 3 days.
Observation index: symptom and sign comprise generate heat, dry pharynx pain, have a headache, watery nasal discharge of having a stuffy nose, cough, sweating, aversion to wind, thirsty, weak, limb aching pain, general malaise, the hyperemia of pharynx mucosa, picture of the tongue, pulse condition.
Clinical efficacy evaluation criteria: cure: in treatment 3d, temperature recovery is normal, and clinical symptoms all disappears, and symptom is without recurrent exerbation; Effective: treatment is taken medicine in 2d, and body temperature is down to less than 38 DEG C, whole body or local cardinal symptom significantly alleviate; Effective: in treatment 3d, body temperature is down to less than 38 DEG C, whole body and local cardinal symptom significantly alleviate; Invalid: symptom, without improvement, does not reach above-mentioned standard person for invalid.Cure to add and effectively add up to total effective rate.
Clinical observation result is in table 6.
Table 6 liang group patient clinical comparitive study (example, %)
Group number of cases cures effective enabledisable total effective rate
Treatment group 60 43(71.67) 11(18.33) 4(6.67) 2(3.33) 54(90.00)
Matched group 60 38(63.33) 14(23.33) 3(5.00) 5(8.33) 52(86.67)
Untoward reaction: two groups of therapeutic processes are showed no any untoward reaction.
This result of study shows: the cure rate for the treatment of group is 71.67%, and obvious effective rate is 18.33%, and total effective rate is 90.00%, and the cure rate of matched group is 63.33%, and obvious effective rate is 23.33%, and total effective rate is 86.67%.All there is not any untoward reaction in two groups of patients.Therefore, it is definite that grippal clinical efficacy treated by Tibetan medicine embodiment 1 powder of the present invention, and safety is high.
In the preparation of conventional oral solid formulation, the preparation of powder be in other conventional oral solid formulation preparation process before process portion, the test example of powder demonstrates has good effect in treatment influenza, also just describes the pill in conventional oral solid formulation, granule, capsule, tablet also have same effect; Namely the above-mentioned embodiment 1-5 enumerated has same effect.Illustrate that Tibetan medicine of the present invention has good effect in treatment influenza.

Claims (4)

1. treat the preparation method of influenza Tibetan medicine for one kind, it is characterized in that comprising the following steps: that this Tibetan medicine is made up of active component or is made up of active component and pharmaceutically acceptable adjuvant, wherein said active component is made up of the crude drug of following concrete weight proportion: Radix aconiti szechenyiani seedling 2.5 ~ 7.5g, Radix Asteris poliothamni 30 ~ 90g, wall tapestry 20 ~ 60g, Radix phlomidis younghusbandii 25 ~ 75g, Radix Codonopsis Convolvulaceae 25 ~ 75g, Leontopodium leontopodioides (Willd.) Beauv. 20 ~ 60g, Pseudobulbus Bletillae (Rhizoma Bletillae) 15 ~ 45g, pectinate rockfoil 15 ~ 45g, assorted flower Radix Gentianae 15 ~ 45g; Mixing, adopts comminuting method or decoction and alcohol sedimentation technique or ethanol extract from water precipitation to make active component.
2. the preparation method of Tibetan medicine according to claim 1, wherein takes the crude drug of following concrete weight proportion: Radix aconiti szechenyiani seedling 4 ~ 6g, Radix Asteris poliothamni 48 ~ 72g, wall tapestry 32 ~ 48g, Radix phlomidis younghusbandii 40 ~ 60g, Radix Codonopsis Convolvulaceae 40 ~ 60g, Leontopodium leontopodioides (Willd.) Beauv. 32 ~ 48g, Pseudobulbus Bletillae (Rhizoma Bletillae) 24 ~ 36g, pectinate rockfoil 24 ~ 36g, assorted flower Radix Gentianae 24 ~ 36g.
3. the preparation method of Tibetan medicine according to claim 2, wherein takes the crude drug of following concrete weight: Radix aconiti szechenyiani seedling 5g, Radix Asteris poliothamni 60g, wall tapestry 40g, Radix phlomidis younghusbandii 50g, Radix Codonopsis Convolvulaceae 50g, Leontopodium leontopodioides (Willd.) Beauv. 40g, Pseudobulbus Bletillae (Rhizoma Bletillae) 30g, pectinate rockfoil 30g, assorted flower Radix Gentianae 30g.
4., according to the preparation method of any one Tibetan medicine described in claim 1-3, it also comprises the following steps: active component and pharmaceutically acceptable adjuvant to make powder, pill, granule, capsule or tablet.
CN201410564895.1A 2014-10-22 2014-10-22 Preparation method of Tibetan drug for treating influenza Pending CN104258085A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201410564895.1A CN104258085A (en) 2014-10-22 2014-10-22 Preparation method of Tibetan drug for treating influenza

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201410564895.1A CN104258085A (en) 2014-10-22 2014-10-22 Preparation method of Tibetan drug for treating influenza

Publications (1)

Publication Number Publication Date
CN104258085A true CN104258085A (en) 2015-01-07

Family

ID=52149742

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201410564895.1A Pending CN104258085A (en) 2014-10-22 2014-10-22 Preparation method of Tibetan drug for treating influenza

Country Status (1)

Country Link
CN (1) CN104258085A (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102526236A (en) * 2012-01-17 2012-07-04 久美彭措 Pharmaceutical formulation for treating influenza and preparation method thereof
CN103316086A (en) * 2013-07-17 2013-09-25 宋永心 Tibetan medicine for treating influenza and preparation method thereof
CN103623065A (en) * 2013-12-05 2014-03-12 淄博职业学院 Medicine composition for treating influenza

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102526236A (en) * 2012-01-17 2012-07-04 久美彭措 Pharmaceutical formulation for treating influenza and preparation method thereof
CN103316086A (en) * 2013-07-17 2013-09-25 宋永心 Tibetan medicine for treating influenza and preparation method thereof
CN103623065A (en) * 2013-12-05 2014-03-12 淄博职业学院 Medicine composition for treating influenza

Similar Documents

Publication Publication Date Title
CN103316086B (en) Tibetan medicine for treating influenza and preparation method thereof
CN105169017A (en) Traditional Chinese medicine for treating kidney stone and preparation method of traditional Chinese medicine
CN101628108B (en) Traditional Chinese medicinal granules for treating wind-cold evil and preparation method thereof
CN105535738A (en) Traditional Chinese medicine preparation for treating chronic cough and preparing method thereof
CN102526236B (en) Pharmaceutical formulation for treating influenza and preparation method thereof
CN103301271A (en) Tibetan medicine for treating pharyngitis and preparation method thereof
CN105616754A (en) Pill medicine for treating wind-heat attacking upward syndrome and preparation method thereof
CN104983968A (en) Pyretolysis traditional Chinese medicine composition and preparation method
CN104800655A (en) Traditional Chinese medicine for treating infantile pneumonia
CN104258086A (en) Tibetan medicine for curing influenza
CN103330767A (en) Tibetan medicine for curing cough and preparing method thereof
CN103948899B (en) A kind of Tibetan medicine for the treatment of atrophic gastritis
CN102552807A (en) Chinese medicine for curing air temperature type flue and preparation method and application thereof
CN103463517B (en) Medicament for treating asthma
CN103721095B (en) Be used for preventing grippal Chinese medicine preparation
CN105327182A (en) Medicine for treating child pertussis and preparation method thereof
CN104258085A (en) Preparation method of Tibetan drug for treating influenza
CN101112508A (en) Traditional Chinese medicine for treating hyperkinetic syndrome of children
CN103721058A (en) Traditional Chinese medicine preparation for preventing influenza viruses
CN109663012A (en) Dispelling wind and heat, removing toxic substances relieving sore-throat Chinese medicine composition and the preparation method and application thereof
CN101829185B (en) Medicinal composition for resisting influenza virus
CN106924399A (en) It is a kind of to treat endo-medicine of chronic simple pharyngitis and preparation method thereof
CN105232816A (en) Traditional Chinese medicine for treating vocal cord paralysis
CN105169009A (en) Application of traditional Chinese medicine composition in preparation of medicine for treating viral influenza
CN111759938A (en) Traditional Chinese medicine composition for treating children sexual precocity and preparation method thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20150107

RJ01 Rejection of invention patent application after publication